Table 4 Classification of extensively targeted immunotherapy (‐mab) by approved indication, target malignant cell receptor, and mechanism of action
From: Review of cancer therapies for the perioperative physician
Cancer | Name | Trade name | Target cell receptor | Mechanism of action |
|---|---|---|---|---|
Multiple myeloma | Elotuzumab Daratumumab | Empliciti Darzalex | SLAMF7 CD38 | NK, ADCC Apoptosis, ADCC |
Acute lymphocytic leukemia | Blinatumomab | Blincyto | CD19/CD3 | Granzyme and perforin cell-induced death |
Chronic lymphocytic leukemia | Rituximab Alemtuzumab Obinutuzumab Ofatumumab | Rituxan Campath Gazeva Arzerra | CD20 CD52 CD20 CD20 | ADCC ADCC ADCC ADCC |
Non‐Hodgkin’s lymphoma | Ibritumomab | Zevalin | CD20 | B‐emission cell death |
Stem cell transplant failure | Brentuximab | Adcetris | CD30 | Apoptosis |
Colorectal | Cetuximab Bevacizumab Panitumumab Ramucirumab | Erbitux Avastin Vectibix Cyramza | EGFR VEGF‐A EGFR VEGFR2 | Blocks phosphorylation Inhibits angiogenesis & metastatic disease |
Head & neck | Cetuximab | Erbitux | EGFR | Blocks phosphorylation |
Lung | Bevacizumab Pembrolizumab Necitumumab Nivolumab Ramucirumab Atezolizumab | Avastin Keytruda Portrazza Opdivo Cyramza Tecentriq | VEGF‐A PD‐1 EGFR PD‐1 VEGFR2 PD‐1, CD80 | Inhibits angiogenesis Apoptosis Prevents inhibition of antitumor immune response Antitumor growth |
Breast | Bevacizumab Pertuzumab Trastuzumab Ado‐trastuzumab Pembrolizumab Atezolizumab Avelumab Durvalumab | Avastin Perjeta Herceptin Kadcyla Keytruda Tecentriq Bavencio Infinzi | VEGF‐A HER2 HER2 HER2 PDL-1 PDL-1 PDL-1 PDL-1 | Inhibits angiogenesis Apoptosis ADCC Apoptosis |
Ovarian, peritoneal, glioblastoma | Bevacizumab | Avastin | VEGF‐A | Inhibits angiogenesis & metastatic disease |
Melanoma | Pembrolizumab Ipilimumab Nivolumab | Keytruda Yervoy Opdivo | PD‐1 CTLA‐4 PD‐1 | Prevents inhibition of antitumor immune response |
Gastric | Trastuzumab Ramucirumab | Herceptin Cyramza | HER2 VEGFR2 | ADCC Inhibits angiogenesis |
Solid tumor bone metastasis | Denosumab | Prolia Xgeva | RANKL | Antitumor growth |
Urothelial | Atezolizumab | Tecentriq | PD‐1, CD80 | Antitumor growth |
Malignant ascites | Catumaxomab | Removab | CD3 | T-cell-induced death |